STOCK TITAN

Vanguard disaggregates holdings; reports 0 shares of Organon (OGN)

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Organon & Co ownership update: The Vanguard Group filed an amendment noting an internal realignment on January 12, 2026 that led certain subsidiaries and business divisions to report beneficial ownership separately under SEC Release No. 34-39538. The filing states The Vanguard Group beneficially owns 0 shares of Organon common stock, representing 0% of the class. The statement explains the subsidiaries pursue the same investment strategies previously used and that Vanguard Inc. no longer is deemed to beneficially own those securities. The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.

Positive

  • None.

Negative

  • None.





68622V106

(CUSIP Number)
03/13/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/27/2026

FAQ

What does Vanguard's Schedule 13G/A for OGN state?

It reports beneficial ownership of 0 shares and 0%. The filing says an internal realignment on January 12, 2026 caused certain subsidiaries to report separately under SEC Release No. 34-39538, and Vanguard Inc. is no longer deemed to beneficially own those securities.

Does the filing indicate Vanguard subsidiaries still follow the same strategies?

Yes — the filing states they pursue the same investment strategies. It explains the subsidiaries or business divisions continue prior strategies even after disaggregation, per the referenced SEC release.

Who signed the Schedule 13G/A amendment for Vanguard on OGN?

The filing is signed by Ashley Grim, Head of Global Fund Administration. The signature block shows the filing date as 03/27/2026, attesting to the reported ownership information.

Does Vanguard report any >5% holder or third-party interests for OGN?

No other person is reported with more than 5% interest. The filing states no one else's interest exceeds 5%, and Vanguard notes the right to receive dividends or sale proceeds for managed accounts and registered investment companies.

What is the effect of SEC Release No. 34-39538 mentioned in the filing?

It permits disaggregated reporting by subsidiaries or business divisions. The filing cites the release to explain why certain Vanguard subsidiaries now report beneficial ownership separately from The Vanguard Group, Inc.
ORGANON & CO

NYSE:OGN

View OGN Stock Overview

OGN Rankings

OGN Latest News

OGN Latest SEC Filings

OGN Stock Data

1.57B
259.24M
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
JERSEY CITY